Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of SD-809 in Tourette Syndrome
NCT02674321Phase 1Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deutetrabenazine in Tourette syndrome (TS), sponsored by Auspex Pharmaceuticals. Primary endpoint: Safety and Tolerability at 8 weeks. Started Jul 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02674321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674321.